Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10045175 | 0.98 | L3MBTL1 (0.55) | L3MBTL1CHRM2SMN1; SMN2HRH4HRH3 | |
| SCHEMBL10045180 | 0.98 | L3MBTL1 (0.55) | L3MBTL1CHRM2SMN1; SMN2HRH4HRH3 | |
| SCHEMBL10045172 | 0.98 | L3MBTL1 (0.55) | L3MBTL1CHRM2SMN1; SMN2HRH4HRH3 | |
| SCHEMBL10045143 | 0.93 | L3MBTL1 (0.64) | L3MBTL1CHRM2SMN1; SMN2HRH4HRH3 | |
| SCHEMBL10045173 | 0.91 | L3MBTL1 (0.62) | L3MBTL1CHRM2SMN1; SMN2HRH4HRH3 | |
| SCHEMBL10045171 | 0.91 | L3MBTL1 (0.62) | L3MBTL1CHRM2SMN1; SMN2HRH4HRH3 | |
| SCHEMBL10045072 | 0.88 | SMN1; SMN2 (0.65) | L3MBTL1CHRM2SMN1; SMN2HRH4HRH3 | |
| SCHEMBL8278011 | 0.85 | L3MBTL1 (0.58) | L3MBTL1SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL10045170 | 0.83 | L3MBTL1 (0.54) | L3MBTL1CHRM2SMN1; SMN2HRH4HRH3 | |
| SCHEMBL29579969 | 0.83 | L3MBTL1 (0.70) | L3MBTL1CHRM2SMN1; SMN2HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148577-B2 | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148577-B2 | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-10-28 | — | — | US | disclosed |
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | JOHN HOPKINS UNIVERSITY (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | JOHN HOPKINS UNIVERSITY (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2007021839-A2 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | JOHNS HOPKINS UNIVERSITY (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | KDM1A, JMJD6, SRM | L3MBTL1 209/4885CHRM2 3888/4885SMN1; SMN2 3337/4885 |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | KDM1A, JMJD6, SRM | L3MBTL1 209/4885CHRM2 3888/4885SMN1; SMN2 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.